Increasing Treatment Uptake for Chronic Hepatitis B in South America: A Comparative Analysis of Country‐Specific and WHO 2024 Guidelines
- 26 May 2025
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 32 (6) , e70035
Abstract
The 2024 WHO guidelines for chronic hepatitis B ( CHB ) aim to expand and simplify treatment eligibility. We aimed to estimate treatment eligibility and uptake according to country‐specific guidelines and evaluate treatment expansion based on the WHO guidelines. Treatment‐naïve CHB patients from Argentina, Brazil, Chile and Uruguay referred to evaluation between January 2010 and June 2024 were retrospectively included. Treatment candidacy was evaluated according to both country‐specific and WHO guidelines. A total of 719 patients with CHB , treatment naïve, were included (67.1% male; median age: 50.4 years; HBeAg ‐positive: 36.3%). The median HBV ‐ DNA level was 43,000 ( IQR 633–110,000,000) IU /mL, median ALT was 41 ( IQR 23–99) U/L, 47.0% had an APRI > 0.5 and 21.1% had cirrhosis. According to country‐specific guidelines, 56.9% (95% CI : 53.2–60.5) met the criteria for treatment. Antiviral treatment was initiated in 84.3% of eligible patients. The proportion of patients meeting treatment criteria under the WHO guidelines increased to 67.3% (95% CI : 63.8–70.6), resulting in a 10.4% (95% CI : 8.1–12.8) increase in treatment candidacy. Treatment expansion was significantly higher in women (15.2%; 95% CI : 10.2–20.1) than in men (8.1%; 95% CI : 5.4–10.7). According to WHO guidelines, a considerable proportion of CHB patients who do not meet country‐specific criteria are eligible for antiviral therapy. Implementing WHO criteria can enhance treatment rates and advance efforts toward CHB elimination.Keywords
This publication has 16 references indexed in Scilit:
- The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: Main changes and potential implications for the next major liver society clinical practice guidelinesJournal of Hepatology, 2024
- WHO 2024 Hepatitis B Guidelines and Treatment-Eligible Rate Among Treatment-Naive PatientsJAMA Network Open, 2024
- Steatosis, HBV‐related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta‐analysisHepatology, 2023
- Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care centerUnited European Gastroenterology Journal, 2023
- Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008–2012: A cross-sectional studyJHEP Reports, 2022
- Recent molecular evolution of hepatitis B virus genotype F in Latin AmericaArchives of Virology, 2022
- Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2021
- Poor Adherence to Guidelines for Treatment of Chronic Hepatitis B Virus Infection at Primary Care and Referral PracticesClinical Gastroenterology and Hepatology, 2019
- EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosisJournal of Hepatology, 2018
- EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosisJournal of Hepatology, 2015